Evaluation of ranibizumab-induced changes in high- resolution optical coherence tomographic retinal morphology and their impact on visual function

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 5, 2009, Pages 2376-2383

  Kiss, Christopher G ^a   Geitzenauer, Wolfgang ^a   Simader, Christian ^a   Gregori, Giovanni ^b   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATHOLOGICAL ANATOMY; PATIENT MONITORING; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; RETINAL FUNCTION; RETINAL MORPHOLOGY; RISK REDUCTION; SCOTOMA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; THICKNESS; TREATMENT DURATION; VISION; VISUAL ACUITY; DRUG ANTAGONISM; FLUORESCENCE ANGIOGRAPHY; INJECTION; PATHOLOGY; PATHOPHYSIOLOGY; PERIMETRY; PHYSIOLOGY; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; PERIMETRY; RETINA; RETINAL PIGMENT EPITHELIUM; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 65549147695     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2017     Document Type: Article

References (27)

1. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37: 1929-1934.
2. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
3. Cui JZ, Kimura H, Spee C, Thumann G, Hinton DR, Ryan SJ. Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate. Graefes Arch Clin Exp Ophthalmol. 2000;238:326-333.
4. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115-134.
5. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508 e1501-1525.
6. D'Amico DJ, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113: 1001,e1001-e1006.
7. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870.
8. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113: 642 e641-644.
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
10. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
11. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:632 e631.
12. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-1053.
13. Heier JS, Rosenfeld PJ, Antoszyk AN, Hantsbarger G, Kim R, Shams N. Long-term experience with Lucentis (ranibizumab) in patients with neovascular age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci. 2005;46:1393-.
14. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
15. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol. 2008;92:361-364.
16. Midena E, Vujosevic S, Convento E, Manfre A, Cavarzeran F, Pilotto E. Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration. Br J Ophthalmol. 2007;91: 1499-1503.
17. Springer C, Bultmann S, Volcker HE, Rohrschneider K. Fundus perimetry with the micro perimeter 1 in normal individuals: comparison with conventional threshold perimetry. Ophthalmology. 2005;112:848-854.
18. Midena E, Radin PP, Pilotto E, Ghirlando A, Convento E, Varano M. Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration: a microperimetry study. Semin Ophthalmol. 2004; 19:55-61.
19. Rohrschneider K, Springer C, Bultmann S, Volcker HE. Microperimetry: comparison between the micro perimeter 1 and scanning laser ophthalmoscope-fundus perimetry. Am J Ophthalmol. 2005;139:125-134.
20. Legaretta JE, Gregori G, Knighton RW, Punjabi OS, Lalwani GA, Puliafito CA. Three-dimensional spectral-domain optical coherence tomography images of the retina in the presence of epiretinal membranes. Am J Ophthalmol. 2008;145:1023-1030.
21. Leung CK, Cheung CY, Weinreb RN, et al. Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2008;49(11):4893-4897.
22. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005;85:845-881.
23. Timberlake GT, Peli E, Essock EA, Augliere RA. Reading with a macular scotoma. II. Retinal locus for scanning text. Invest Ophthalmol Vis Sci. 1987;28:1268-1274.
24. Kiss CG, Barisani-Asenbauer T, Maca S, Richter-Mueksch S, Radner W. Reading performance of patients with uveitis-associated cystoid macular edema. Am J Ophthalmol. 2006;142:620-624.
25. Kiss CG, Barisani-Asenbauer T, Simader C, Maca S, Schmidt-Erfurth U. Central visual field impairment during and following cystoid macular oedema. Br J Ophthalmol. 2008;92:84-88.
26. Tezel TH, Del Priore LV, Flowers BE, et al. Correlation between scanning laser ophthalmoscope microperimetry and anatomic abnormalities in patients with subfoveal neovascularization. Ophthalmology. 1996;103:1829-1836.
27. Schneider U, Inhoffen W, Gelisken F, Kreissig I. Assessment of visual function in choroidal neovascularization with scanning laser microperimetry and simultaneous indocyanine green angiography. Graefes Arch Clin Exp Ophthalmol. 1996;234:612-617.